It has been reported that CCL2 expression is often higher in drug-resistant tumor cell lines than in drug-sensitive tumor cell lines, and silencing or blockade of its expression can re-sensitize cancer cells to anticancer treatment [27,28,29,30]. The gene discussed is CCL2; the disease is cancer.